Physician profile
Jenna Emerson
NPI 1457791154
$1,661.82
in general payments reported to CMS, 2019-2025
10 companies · $1,005 in 2025
The $1,005 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2021: $73.60 · 2022: $20.86 · 2023: $153 · 2024: $183 · 2025: $1,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $665 · Food and Beverage: $512 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $664.65 |
| Food and Beverage | $512.39 |
| Education | $164.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $842.12 | 2019-2025 | |
| Glaxosmithkline, LLC. | $183.30 | 2024 | Zejula |
| Caris Mpi, INC. | $144.30 | 2025 | Mi Cancer Seek |
| Foundation Medicine, INC. | $109.24 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Tesaro, INC. | $92.65 | 2019 | |
| Coopersurgical, INC. | $73.60 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $71.18 | 2025 | Lynparza |
| Pfizer INC. | $24.62 | 2025 | |
| Merck Sharp & Dohme LLC | $20.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Emerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.